Comparison of T-Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease
- 1 December 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (4) , 296-305
- https://doi.org/10.1097/00126334-200012010-00002
Abstract
This research comprised a pilot open prospective clinical study comparing T-cell subset reconstitution in antiretroviral-naive patients, after 12 months of HAART when treatment was initiated in early stages (ES; n = 18) of infection versus advanced stages (AS; n = 20). Control group: 10 healthy HIV-negative individuals. Immunophenotypic markers were evaluated before and after 6- and 12-months' therapy. Functional assays were performed in one subset. Viral load (VL) was < 200 copies/ml in all patients. Median percentages of CD4+ pretherapy were 33% and 6%, respectively, in the ES and AS groups, increment after 12 months of therapy was +15% and +13% respectively. Only the ES group achieved normal values. Declines of CD8+ percentage were significantly higher in the ES (-18%) than in the AS group (-2%). CD4+ memory and naive cells in the ES group were similar to those of controls before treatment and did not change after therapy. In contrast, CD4+ memory and naive cells in the AS group did not reach normal levels despite treatment. In the ES group, there was a significant increment in CD8+ naive cells (+8%) and a decrement in CD8+CD38+ cells (-17%), both populations reached values close to normal, whereas these subsets remained far from normal in the AS group. Improvement of lymphoproliferative response after therapy was observed in both groups. One patient in the ES group showed positive LPR against p24 after treatment. After 12 months' highly active antiretroviral therapy, only those who began such therapy in ES disease reached values within the range of healthy controls. To achieve a more complete immunologic reconstitution, early initiation of potent antiretroviral therapy should be recommended.Keywords
This publication has 26 references indexed in Scilit:
- Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapyAIDS, 1999
- Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalitiesAIDS, 1998
- Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection.Journal of Clinical Investigation, 1998
- Patterns of Virus Burden and T Cell Phenotype Are Established Early and Are Correlated with the Rate of Disease Progression in Human Immunodeficiency Virus Type 1-Infected PersonsThe Journal of Infectious Diseases, 1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- Correlation of CD8 Lymphocyte Activation with Cellular Viremia and Plasma HIV RNA Levels in Asymptomatic Patients Infected by Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1996
- CD8 naive T cell counts decrease progressively in HIV-infected adults.Journal of Clinical Investigation, 1995
- Expression of CD28 on CD8+ and CD4+ Lymphocytes During HIV InfectionScandinavian Journal of Immunology, 1994
- Expression of Costimulatory Molecule CD28 on T Cells in Human Immunodeficiency Virus Type 1 Infection: Functional and Clinical CorrelationsThe Journal of Infectious Diseases, 1994
- CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.The Journal of Experimental Medicine, 1992